ClinicalTrials.gg
CompletedNCT06166056Updated Oct 26, 2026

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

A Phase 1/2 interventional study of CHF6333 and CHF6333 Placebo in Bronchiectasis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 8 sites in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1/2, Interventional, and Treatment

Updated Oct 26, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Bronchiectasis with a site in United Kingdom — 18 open to participants now, 19 under way, 2 of them phase 3. Bronchiectasis · United Kingdom.

Enrollment
21st of 52
108 · median 89
Started
2023
with 1 other
Phase 1/2
Only one
of the 73
Registered
56th of 73
by date

Among the 73 studies in Bronchiectasis with a site in United Kingdom, this one is the 21st largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1/2, and was the 56th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

18 of the 73 studies in Bronchiectasis with a site in United Kingdom are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Bronchiectasis with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this clinical trial is to assess the safety of:

  • single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I
  • repeated doses of the study drug CHF6333 in subjects with BE - Part II
03

Conditions studied

  • Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

HV Inclusion Criteria:

  1. Signed and dated obtained prior to any study-related procedure;
  2. Healthy male or female subject ≥18 and ≤60 years of age at screening;
  3. Ability to understand the study procedures and the risks involved, and to be trained to use inhalers correctly and to generate sufficient peak inspiratory flow (PIF) (at least 40 L/min) using the In-Check Dial set as per "GenuAir" inhaler resistance, at screening;
  4. (BMI) ≥18 and ≤35 kg/m2 at screening;
  5. Non-smokers or ex-smokers who smoked \<5 pack-years and stopped smoking >1 year prior to screening;
  6. Good physical and mental status, determined via assessment of medical history and clinical examination, at screening and prior to randomisation;
  7. Vital signs within normal limits at screening and prior to randomisation: diastolic blood pressure (DBP) ≥40 and ≤89 mmHg, and systolic blood pressure (SBP) ≥90 and ≤139 mmHg; body temperature \<37.5°C;
  8. Triplicate 12-lead (ECG) considered as normal (40 ≤ heart rate ≤110 bpm, 120 ms ≤ PR ≤210 ms, QRS ≤120 ms, Fridericia interval [QTcF] ≤450 ms for males and QTcF ≤470 ms for females) at screening and prior to randomisation;
  9. Lung function measurements within limits at screening and prior to randomisation: (FEV1) >80% predicted and FEV1/forced vital capacity (FVC) ratio >0.70;
  10. Male subjects willing to use a male condom throughout the study if they have women of (WOCBP) partners; male subjects with non-WOCBP partners or who are sterile do not have requirements;
  11. Female subjects (if WOCBP) and/or their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements.

HV Exclusion Criteria:

  1. Participation in another clinical study where drug was received and the last investigations were performed less than 3 months prior to randomisation;
  2. and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, hematologic, metabolic, neurological, or psychiatric disorders that may interfere with successful completion of this protocol, according to the investigator's judgment;
  3. Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the results of the study, according to the investigator's judgment;
  4. History of respiratory diseases;
  5. Positive (HIV) 1 or HIV2 serology results at screening;
  6. Hepatitis serology results which indicate acute or chronic (HB) or virus (HCV) at screening;
  7. Documented coronavirus disease 2019 (COVID-19) diagnosis within 2 weeks prior to screening or prior to randomisation, or associated complications/symptoms, which have not resolved within 2 weeks prior to screening;
  8. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior to screening or prior to randomisation;
  9. Abnormal liver enzymes at screening or prior to randomisation ( [ALT] or aspartate aminotransferase [AST] or : >1.5× [ULN]);
  10. Positive urine test for cotinine at screening or prior to randomisation;
  11. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test at screening or prior to randomisation;
  12. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen at screening or prior to randomisation;
  13. Treatment with prohibited concomitant medications or if the subject is expected to take prohibited concomitant medications during the study;
  14. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or prior to randomisation;
  15. Known intolerance and/or to any of the contained in the formulation used in the study;
  16. Unsuitable veins for repeated venepuncture;
  17. Heavy caffeine drinker;
  18. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. A serum pregnancy test is to be performed at screening and a urine pregnancy test is to be performed prior to randomisation;
  19. Use of any kind of electronic smoking devices within 6 months prior to screening.

Part I BE subjects Inclusion Criteria:

  1. Signed and dated informed consent obtained prior to any study-related procedure;
  2. Male or female subject ≥18 and ≤80 years of age at screening;
  3. Clinical history consistent with BE (cough, chronic sputum production, and/or recurrent respiratory infections) that is confirmed by chest computed tomography (CT) demonstrating BE affecting 1 or more lobes (confirmation may be based on prior chest CT); subjects whose past chest radiographic image records or report are not available will undergo chest CT scan during screening;
  4. Post-bronchodilator FEV1 ≥50% of the predicted value at screening;
  5. If currently receiving treatment for BE, this treatment should be administered at a stable dose;
  6. Subjects in a stable clinical condition with no exacerbation of BE for at least 4 weeks prior to randomisation. A pulmonary exacerbation is defined as a deterioration in three or more of the key symptoms for at least 48 hours (cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, haemoptysis) AND a clinician-prescribed course of antibiotics;
  7. Vital signs within normal limits at screening and prior to randomisation: DBP ≥40 and ≤89 mmHg, and SBP ≥90 and ≤150 mmHg; body temperature \<37.5°C;
  8. Ability to understand the study procedures and the risks involved, and the ability to be trained to use the inhalers correctly and to generate sufficient PIF (at least 40 L/min) using the In-Check Dial set as per "GenuAir" inhaler resistance, at screening;
  9. Male subjects willing to use a male condom throughout the study if they have WOCBP partners; male subjects with non-WOCBP partners or who are sterile do not have contraception requirements;
  10. Female subjects (if WOCBP) and/or their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements.

Part I BE subjects Exclusion Criteria:

  1. History of a clinically meaningful unstable or uncontrolled chronic comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering the study drug to the subject;
  2. Acute symptomatic respiratory tract infection which constitutes an increase from the subject's baseline, per the investigator's judgment, within 4 weeks prior to randomisation;
  3. Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation that results in an active medical problem, which may impact the safety of the subject, per the investigator's judgment. Male subjects with QTcF >450 ms and female subjects with QTcF >470 ms cannot be enrolled;
  4. Clinically significant abnormal laboratory values at screening that, in the opinion of the investigator, may put the subject at risk by participating in the study, or interfere with the subject's treatment or assessment, or influence the results of the study;
  5. Participation in another clinical study, where investigational drug was received less than 30 days or less than 5 half-lives of the previous administered product (whichever is longer) prior to screening; participation in another clinical study is also not allowed between screening and randomisation;
  6. Primary diagnosis of asthma, as determined by the investigator;
  7. Concomitant diagnosis of cystic fibrosis;
  8. Diagnosis of (COPD) made by a clinician, with airflow obstruction (post-bronchodilator FEV1/FVC ratio \<0.7) and at least a 10 pack-year smoking history; subjects with documented COPD but without airflow obstruction or smoking history will be permitted;
  9. Current smokers; ex-smokers must have stopped for at least 1 year prior to screening (≥6 months for electronic smoking devices);
  10. Subjects with an active tuberculous mycobacteria (TM) or non-tuberculous mycobacteria (NTM) infection requiring or receiving antibiotic treatment, an active allergic bronchopulmonary aspergillosis requiring treatment with or anti-fungal therapy, and/or a connective tissue disease (CTD) receiving an treatment equivalent to >10 mg prednisolone daily or systemic immunosuppression;
  11. Diagnosis of common variable immunodeficiency (CVID) or other immunodeficiencies requiring immunoglobulin treatment, based on subject history;
  12. Diagnosis of rheumatoid arthritis;
  13. that has not been in complete remission for at least 1 year or any untreated localised carcinomas;
  14. History of solid organ/haematological transplantation and receiving immunosuppressive therapy;
  15. Use of any antimicrobials (oral, inhaled, or intravenous) within 4 weeks prior to randomisation, except for subjects who are on stable treatment with macrolide antibiotics (for at least 3 months);
  16. Medical history of discontinuation of previous inhaled therapy due to bronchospasm or intolerance;
  17. Documented COVID-19 diagnosis within 4 weeks prior to randomisation, or associated complications/symptoms;
  18. Diagnosis of alpha-1-antitrypsin (AAT) deficiency defined as an AAT serum level \<110 mg/dL; a prior test result of AAT serum level to confirm the diagnosis will be acceptable. In the event that a prior result is not available, a new test will be performed during the screening period and the result considered for the eligibility at randomisation.
  19. Treatment with prohibited concomitant medications or if the subject is expected to take prohibited concomitant medications during the study;
  20. Subjects treated with monoclonal antibodies (mAbs) for any respiratory conditions;
  21. Subjects with traction BE;
  22. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. A serum pregnancy test is to be performed at screening, and a urine pregnancy test is to be performed prior to randomisation;
  23. Positive HIV1 or HIV2 serology results at screening;
  24. Hepatitis serology results which indicate acute or chronic HB or HCV at screening;
  25. BMI ≤17 kg/m2 at screening.

Part II BE subjects Inclusion Criteria: the subjects must meet all the inclusion criteria listed in Part I for subjects with BE (Cohort B), except the inclusion criterion below:

4. Post-bronchodilator FEV1 ≥30% of the predicted value at screening.

The subjects must also meet the additional inclusion criteria listed below:

11. Subjects who are regular daily sputum producers and who are able to provide at least one sputum sample at screening and two sputum samples prior to randomisation; 12. Subjects with active NE level in sputum sample at screening, defined by either a positive bacterial culture in a local laboratory (a positive result for any pathogen will be accepted for eligibility) or by a positive reading of the NEATstik® research use only test.

Part II BE subjects Exclusion Criteria:

See the list of criteria in Part I for subjects with BE (Cohort B), except the exclusion criterion below:

15. Use of oral or inhaled antibiotics \< 3 months prior to randomization as chronic treatment for BE. Patients on antibiotics as chronic treatment should have been on such treatment for ≥ 3 months prior to randomization while meeting all other inclusion and exclusion criteria.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Experimental: CHF6333

    CHF6333 active (Part I - SAD): once daily inhaled single dose of CHF6333 at each period (three dose levels for HVs and one dose level for BE subjects). CHF6333 active (Part II - MD): once daily inhaled multiple dose of CHF6333 for 28 days consecutive days (two dose levels for BE subjects).

    Drug: CHF6333

  • Placebo comparator
    Placebo comparator: CHF6333 Placebo

    CHF6333 placebo (Part I - SAD): once daily inhaled single dose of placebo matching CHF6333 at each period. CHF6333 placebo (Part II - MD): once daily inhaled multiple dose of placebo matching CHF6333 for 28 days consecutive days.

    Drug: CHF6333 Placebo

Interventions

  • CHF6333 Part I SAD; CHF6333 Part II MD.

  • DrugCHF6333 Placebo

    Placebo Part I SAD; Placebo Part II MD.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of AEs

    Time frame: Through study completion. Part I: an average of 12 weeks and 8 weeks respectively for HVs and BE subjects. Part II: an avarage of 26 weeks

  2. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of vital signs

    Arterial blood pressure (SBP and DBP)

    Time frame: Part I:screening, day(D)-1, D1(from pre-dose until 96hrs post-dose HV, 6hrs post-dose BE), 14 to 21D post-dose.Part II:screening, D-1, D1 and 27(from pre-dose until 6hrs post-dose), D28(from pre-dose until 2hrs post-dose), 14 to 21D after last dose

  3. heart rate (HR)

    Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II).

    Time frame: Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose

  4. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: PR interval

    Part I HVs only and Part II

    Time frame: Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose

  5. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: QRS interval

    Part I HVs only and Part II

    Time frame: Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose

  6. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: Fridericia-corrected QT interval (QTcF)

    Part I HVs only and Part II

    Time frame: Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose

  7. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1

    Time frame: Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose

  8. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FVC

    Time frame: Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose

  9. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1/FVC ratio

    Time frame: Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose

  10. Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1 percentage of predicted

    Time frame: Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose

  11. Number of participants with clinical laboratory tests: Haematology

    Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Haematology

    Time frame: Part I: screening, day-1 and day5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose)

  12. Number of participants with clinical laboratory tests: Biochemistry

    Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Biochemistry

    Time frame: Part I: screening, day-1 and day5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose)

  13. Number of participants with clinical laboratory tests: Urinalysis

    Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Urinalysis

    Time frame: Part I: screening, day-1 and day 5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose)

Secondary outcomes

  1. Pharmacokinetic variables in plasma in HVs only (Part I), in terms of Area Under the Curve

    Area under the plasma concentration versus time curve (AUC) from Time 0 to 30 minutes post-dose (AUC0-30min), AUC from Time 0 to 12 hours post-dose (AUC0-12h), AUC from Time 0 to 24 hours post-dose (AUC0-24h), AUC from Time 0 to 96 hours post-dose (AUC0-96h), AUC from Time 0 to time of last quantifiable concentration (AUC0-t), AUC from Time 0 to infinity (AUC0-∞)

    Time frame: Day 1: from pre-dose until 96 hours post-dose

  2. Pharmacokinetic variables in plasma in HVs only (Part I): Maximum concentration (Cmax)

    Time frame: Day1: from pre-dose until 96 hours post-dose

  3. Pharmacokinetic variables in plasma in HVs only (Part I): Time to maximum concentration (tmax)

    Time frame: Day1: from pre-dose until 96 hours post-dose

  4. Pharmacokinetic variables in plasma in HVs only (Part I): Terminal half-life (t½)

    Time frame: Day 1: from pre-dose until 96 hours post-dose

  5. Pharmacokinetic variables in plasma in HVs only (Part I): Clearance (CL/F)

    Time frame: Day 1: from pre-dose until 96 hours post-dose

  6. Pharmacokinetic variables in plasma in HVs only (Part I): Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Day 1: from pre-dose until 96 hours post-dose

  7. Pharmacokinetics variables in plasma in BE subjects (Part II); in terms of Area Under the Curve

    Day1: AUC0-30min, AUC0-8h, AUC0-t \- Day27: AUC0-30min at steady state (AUC0-30min,ss), AUC0-8h at steady state (AUC0-8h,ss), AUC0-t at steady state (AUC0-t,ss)

    Time frame: At Day1 and 27: from pre-dose until 8 hours post-dose

  8. Pharmacokinetics variables in plasma in BE subjects (Part II): Cmax

    Day1: Cmax \- Day27: Cmax at steady state (Cmax,ss)

    Time frame: At Day1 and 27: from pre-dose until 8 hours post-dose

  9. Pharmacokinetics variables in plasma in BE subjects (Part II): tmax

    Day 1: tmax \- Day27: tmax at steady state (tmax,ss)

    Time frame: At Day 1 and 27: from pre-dose until 8 hours post-dose

  10. Pharmacokinetics variables in plasma in BE subjects (Part II): Ratio of accumulation (Rac) for Cmax and AUC parameters

    Time frame: At Day 1 and 27: from pre-dose until 8 hours post-dose

  11. CHF6333 plasma concentrations (Part II)

    CHF6333 plasma concentrations on Day27 and 28 will be reported.

    Time frame: At Day 27 and 28: 3 hours post-dose

07

Study locations

8 sites
  • Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection
    Cambridge, United Kingdom
  • Tayside Medical Science Centre, Ninewells Hospital & Medical School
    Dundee, United Kingdom
  • NHS Lothian
    Edinburgh, United Kingdom
  • Glasgow Royal Infirmary
    Glasgow, United Kingdom
  • Royal Bromptom Hospital (NHS Guy's and Thomas')
    London, United Kingdom
  • Manchester University NHS Foundation Trust
    Manchester, United Kingdom
  • Medicines Evaluation Unit (MEU)
    Manchester, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Aug 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 12, 2023
StartActual
Nov 29, 2023
Primary completionActual
Aug 27, 2026
CompletionActual
Aug 27, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Sites
1 site removed
Show 1 removed
  • The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital · Leeds, United Kingdom
Oct 26, 2026
Enrollment
45 (estimated)→108 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital · Leeds, United Kingdom
    Enrollment 45 (estimated)→108 (actual)
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06166056
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Nov 29, 2023
Primary completion
Aug 27, 2026
Completion
Aug 27, 2026
Last update
Oct 26, 2026

Study contacts

James D. Chalmers
principal investigator · School of Medicine, University of Dundee, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHF-6333

Start the discussion